Novel targets in non-small cell lung cancer: ROS1 and RET fusions - Wikidata - awgldk - TriplyDB

Novel targets in non-small cell lung cancer: ROS1 and RET fusions

Novel targets in non-small cell lung cancer: ROS1 and RET fusions

http://www.wikidata.org/entity/Q37038500

about

Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.Crizotinib in ROS1-rearranged non-small-cell lung cancer.Testing for ROS1 in non-small cell lung cancer: a review with recommendations Epidemiology of Lung Cancer in Korea: Recent Trends Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors The evolving genomic classification of lung cancer.Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.Tripartite motif-containing 29 as a novel biomarker in non-small cell lung cancer Efficient generation and reversion of chromosomal translocations using CRISPR/Cas technology.A Histopathological Feature of EGFR-Mutated Lung Adenocarcinomas with Highly Malignant Potential - An Implication of Micropapillary Element.The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis.KAOS: a new automated computational method for the identification of overexpressed genes.Dimethylarginine dimethylaminohydrolase 2 promotes tumor angiogenesis in lung adenocarcinoma.ROS1 copy number alterations are frequent in non-small cell lung cancer.The prognostic role of intragenic copy number breakpoints and identification of novel fusion genes in paediatric high grade glioma.Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis.New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs.Lung cancer in women: an overview with special focus on Spanish women.Update on systemic therapy of advanced non-small-cell lung cancer.Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/In Detecting and targetting oncogenic fusion proteins in the genomic era.Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.Emerging paradigms in targeted treatments for Asian patients with NSCLC.Current and future molecular diagnostics in non-small-cell lung cancer.Classification of different patterns of pulmonary adenocarcinomas.Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.Recent Advances in Targeting ROS1 in Lung Cancer.ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives.Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.ROS1 fusions in cancer: a review.Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma.Lung cancer as a paradigm for precision oncology in solid tumours.

P2860

Q26784298-9257687C-CCFE-49E5-B9E1-8AAF845FA638 Q27023383-5F0EF33D-950A-40F5-8462-73B4152E6CAA Q27311389-9161B9C9-3486-4A2E-A64F-5FF4EA98EF61 Q27853075-2E7B71D7-3F7A-47B3-925C-9C548AEBF881 Q28070062-E8921529-EEE3-4242-B340-7ACD389675F8 Q28077423-0CFE553A-CC12-46E2-8C22-0DB2BED4A67F Q28077504-3ACCE2B5-FB42-4AA2-9448-3863F9FDA427 Q34852043-AE8DA74E-E846-499A-9F43-2EBA714203C5 Q35151926-EB05FAB1-49F9-4FB5-A890-F1E8840D7C93 Q35775228-97C615AD-D5D4-4375-9FFE-F101C25C7C6B Q35837200-0176EEF1-036F-40FE-A2EF-AD607785B2CD Q36066539-3A8BA34C-0F03-402F-B688-7A046E7C15D7 Q36085398-5649EA43-16D8-4F44-BF4A-6AD86CB4B40F Q36136571-14972646-8F81-4AA4-B858-70D5421B175D Q36197300-21A83DDD-E81B-4ABA-8460-0C08341BA80D Q36214500-7F0E3CCC-FF0C-4774-B102-C47864E0C3A4 Q36276385-E0065D92-7D98-4BB9-84DE-BF5DEF4F393E Q36651307-39659A19-7F21-4005-AD11-B099E51C1D1A Q36946705-8495BC24-EB35-4184-8B90-052665262C8C Q37609740-D2D26B54-F486-46FE-9E27-F8B0889FE66D Q37644847-9D95E569-BDFC-495B-9B04-2A9BA9FA45BC Q37665468-619D7AF6-EFA3-4829-A501-0F479A4B407F Q37724947-E52C8D5A-86F1-4394-9B1C-49101EBD9E58 Q38166318-891EB203-DEAD-4478-B39A-D50126F5089C Q38237463-699DAC43-EA02-4216-8E35-9F13860409C9 Q38259724-BCDC112D-FE9B-4E63-A6C5-2A07597FAF97 Q38336067-B7F1DA65-7213-45F4-92B9-DFD1540B5E3E Q38390200-6297BDC9-CC85-4AC9-AD0D-FE5A07BFEA7F Q38439446-D8ECE237-A8D5-4C8A-97D2-D96068C68EBD Q38543780-FB547FE5-BCC4-4848-B5A4-412280B2D149 Q38574971-FAADDF22-0473-4406-A6CB-44C1D275CC5D Q38625550-EAEDC1C9-1812-4D12-8559-20185399E58F Q38640765-5702F587-C1E3-493B-BFA6-F15D9C9BE808 Q38651989-85D3E1EA-4D5D-4CC0-8722-FEAD0289C6B2 Q38652369-2380ABF6-6DA1-4960-A657-9B2F168B9839 Q38753582-EABC002D-88BD-4C77-BCFC-A7BA4C63D1F1 Q38785003-7F19CDC4-C9F1-4223-840B-0B224EFF7F99 Q38852070-CCCDB082-AC05-4321-805C-C1984528FF2F Q39126870-44E34F18-7455-4A8B-8C80-8EE0122BB28A Q39449763-DD1E3070-0964-41B0-9460-30888952DF90

P2860

Novel targets in non-small cell lung cancer: ROS1 and RET fusions

http://www.wikidata.org/entity/Q37038500

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 June 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Novel targets in non-small cell lung cancer: ROS1 and RET fusions

@en

Novel targets in non-small cell lung cancer: ROS1 and RET fusions.

@nl

type

label

Novel targets in non-small cell lung cancer: ROS1 and RET fusions

@en

Novel targets in non-small cell lung cancer: ROS1 and RET fusions.

@nl

prefLabel

Novel targets in non-small cell lung cancer: ROS1 and RET fusions

@en

Novel targets in non-small cell lung cancer: ROS1 and RET fusions.

@nl

P1433

Q37038500-590D31AE-276F-4211-AF2D-F792674176C6

P1476

Q37038500-50ABC227-839E-428C-BE22-BEB46FDC938B

P2093

Q37038500-920A7196-EF9F-493E-98CA-C4C507A4127A

Q37038500-AB62654B-F3E3-49CB-B39E-8EAEAD947448

P2860

Q37038500-01757901-07A6-456E-A97B-ABBF719447D8

Q37038500-038C00D7-3712-4308-8A55-18B5FFB1AEA4

Q37038500-04E94387-301B-4EFB-B969-869553DD0B3D

Q37038500-0815F0E6-0843-421E-8165-BF64A6B26855

Q37038500-0C415AE6-0E96-43AA-8701-2E3326C4FFDE

Q37038500-100EB053-F830-4667-B1CC-63D83A21A13E

Q37038500-10226F03-0E17-4B90-9B9F-F0E15D511062

Q37038500-18936965-F20F-4329-9795-A1ABC71F3A0B

Q37038500-1BB9549E-FA0B-45D0-982A-B46F2F6370E5

Q37038500-1EA77FA7-2440-42C5-AD0A-24EF615EB081

P304

Q37038500-E2429DA2-54CE-47C5-9ACB-1D70E602E561

P31

Q37038500-0CCA90AF-10B0-4610-B5CE-D32286D475F6

P356

Q37038500-2776B9F3-5A65-445E-90B6-A98FF6F38DB1

P433

Q37038500-A17EC875-F468-45AA-A8EE-16F6A6C6292D

P478

Q37038500-8838F062-B5C4-4162-AA41-5C05A1E8D4C3

P577

Q37038500-DAC18B50-072C-4E0E-9895-606A253859B6

P698

Q37038500-52F488E9-51B0-44C7-8080-B90E098A5674

P932

Q37038500-5E95292A-E29F-49FD-A47B-B6AE8AD431FA

P356

THEONCOLOGIST.2013-0095

P1433

P1476

Novel targets in non-small cell lung cancer: ROS1 and RET fusions

@en

P2093

Alice T Shaw

http://www.w3.org/2001/XMLSchema#string

Justin F Gainor

http://www.w3.org/2001/XMLSchema#string

P2860

Association of a novel PDZ domain-containing peripheral Golgi protein with the Q-SNARE (Q-soluble N-ethylmaleimide-sensitive fusion protein (NSF) attachment protein receptor) protein syntaxin 6

Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains

ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice

Characterization of an activated human ros gene

Defects in enteric innervation and kidney development in mice lacking GDNF

Mutations of the RET proto-oncogene in Hirschsprung's disease

GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma

Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptorlike molecule

P304

865-875

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2013-0095

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23814043

http://www.w3.org/2001/XMLSchema#string

P932

3720641

http://www.w3.org/2001/XMLSchema#string